Trial Profile
An Open-Label Study of AMG 386 in Combination With Either Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in Subjects With HER2-Positive Locally Recurrent or Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Trebananib (Primary) ; Capecitabine; Lapatinib; Paclitaxel; Trastuzumab
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Adverse reactions
- Sponsors Amgen
- 30 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Oct 2015 Planned End Date changed from 1 Feb 2016 to 1 Nov 2015 as reported by ClinicalTrials.gov
- 10 Aug 2015 Planned End Date changed from 1 Oct 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov